1
Signe M Christensen, Nikolaj Dam Mikkelsen, Miriam Frieden, Henrik Frydenlund Hansen, Troels Koch, Daniel Sejer Pedersen, Christoph Rosenbohm, Charlotte Albaek Thrue, Majken Westergaard: Antisense design. Roche Innovation Center Copenhagen, Fish & Richardson P C, August 30, 2016: US09428534 (2 worldwide citation)

A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/am ...


2
Majken Westergaard, Charlotte Albaek Thrue, Frank Winther Rasmussen, Henrik Frydenlund Hansen: Potent LNA oligonucleotides for the inhibition of HIF-1a expression. ROCHE INNOVATION CENTER COPENHAGEN, Stoel Rives, Loren R Hulse, September 20, 2016: US09447138 (1 worldwide citation)

The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5′-(Tx)GxGxcsasasgscsastscscsTxGxT-3′ and 5′-(Gx)TxTxascstsgscscststscsTxTxA-3′, wherein capital letters designate a beta-D-oxy-LNA nucleotide analogue, small letters designate a 2 ...


3
Signe M Christensen, Nikolaj Dam Mikkelsen, Miriam Frieden, Henrik Frydenlund Hansen, Troels Koch, Daniel Sejer Pedersen, Christoph Rosenbohm, Charlotte Albaek Thrue, Majken Westergaard: Antisense design. Roche Innovation Center Copenhagen, Fish & Richardson P C, July 18, 2017: US09708614 (1 worldwide citation)

A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/am ...


4
WENGEL JESPER, KJEMS JOERGEN: ARN INTERFERANT COURT SEGMENTE A LINTERIEUR, SMALL INTERNALLY SEGMENTED INTERFERING RNA. SANTARIS PHARMA, ROCHE INNOVATION CENTER COPENHAGEN, AIRD & MCBURNEY, May 30, 2017: CA2644347 (1 worldwide citation)

An RNA complex for mediating RNA interference is provided that comprisies a core double-stranded region of between 15 to 40 base pairs. The core double stranded region comprises an antisense strand and a discontinuous passenger strand, that is hybridised to the antisense strand, wherein the disconti ...


5
Elisabeth S Hildebrandt Eriksen, Andreas Petri, Sakari Kauppinen, Niels Abrahamsen, Robert Eldon Lanford: Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon. Roche Innovation Center Copenhagen, Sterne Kessler Goldstein & Fox P L L C, May 19, 2015: US09034837

The present invention provides compositions and methods of treatment of HCV infected subjects that are not sensitive to interferon treatment. Further, compositions and methods are provided for prevention of organ transplant rejection. The compositions of the invention comprise an anti microRNA-122 o ...


6
Majken Westergaard, Charlotte Albaek Thrue, Frank Rasmussen, Henrik Frydenlund Hansen: Potent LNA oligonucleotides for the inhibition of HIF-1A expression. Roche Innovation Center Copenhagen, April 10, 2018: US09938527

The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5′-(Tx)GxGxcsasasgscsastscscsTxGxT-3′ and 5′-(Gx)TxTxascstsgscscststscsTxTxA-3′, wherein capital letters designate a beta-D-oxy-LNA nucleotide analog, small letters designate a 2-d ...


7
Signe M Christensen, Nikolaj Dam Mikkelsen, Miriam Frieden, Henrik Frydenlund Hansen, Troels Koch, Daniel Sejer Pedersen, Christoph Rosenbohm, Charlotte Albaek Thrue, Majken Westergaard: Antisense design. Roche Innovation Center Copenhagen, Fish & Richardson P C, February 13, 2018: US09890383

A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/am ...


8
Joacim Elmen, Claes Wahlestedt, Zicai Liang, Anders M Sorensen, Henrik Orum, Troels Koch: Short interfering RNA (siRNA) analogues. Roche Innovation Center Copenhagen, Fish & Richardson P C, March 29, 2016: US09297010

The present invention is directed to novel double-stranded short interfering (siRNA) analogs comprising locked nucleic acid (LNA) monomers. Such compounds induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). The compounds disc ...


9
Gregroy Hardee, Ellen Marie Straarup, Marie Wickstrom Lindholm, Henrik Orum, Henrik Hansen: Oral delivery of therapeutically effective LNA oligonucleotides. Roche Innovation Center Copenhagen, Fish & Richardson P C, June 14, 2016: US09364495

The invention provides for LNA oligomers, for the treatment of a metabolic or liver disorder, wherein the LNA oligomer is administered orally in a unit dose of less than 50 mgs/kg, wherein the LNA oligomer is administered in the presence of a penetration (permeation) enhancer.


10
Niels Fisker Nielsen, Ellen Marie Straarup, Marie Wickstrom Lindholm: Potent anti APOB antisense compounds. Roche Innovation Center Copenhagen, Fish & Richardson P C, March 22, 2016: US09290758

The present invention relates to oligomer compounds (oligomers), which target APO-B100 mRNA in a cell, leading to reduced expression of APO-B100. Reduction of APO-B100 expression is beneficial for the treatment of certain medical disorders, such as diseases associated with apolipoproteinB activity, ...